Nuveen Asset Management LLC Has $6.39 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Nuveen Asset Management LLC increased its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Rating) by 803.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 356,687 shares of the company’s stock after purchasing an additional 317,200 shares during the period. Nuveen Asset Management LLC’s holdings in Amylyx Pharmaceuticals were worth $6,385,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AMLX. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Amylyx Pharmaceuticals during the third quarter worth about $51,000. High Net Worth Advisory Group LLC grew its stake in Amylyx Pharmaceuticals by 33.3% during the third quarter. High Net Worth Advisory Group LLC now owns 2,000 shares of the company’s stock worth $56,000 after buying an additional 500 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in Amylyx Pharmaceuticals by 177.6% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,207 shares of the company’s stock worth $62,000 after buying an additional 1,412 shares during the last quarter. Amalgamated Bank grew its stake in Amylyx Pharmaceuticals by 213.5% during the third quarter. Amalgamated Bank now owns 4,778 shares of the company’s stock worth $135,000 after buying an additional 3,254 shares during the last quarter. Finally, Seven Eight Capital LP bought a new stake in Amylyx Pharmaceuticals during the third quarter worth about $340,000. Institutional investors and hedge funds own 70.55% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 7.5 %

Shares of AMLX stock opened at $30.66 on Monday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $6.51 and a 52-week high of $41.93. The firm’s 50 day moving average price is $36.16 and its two-hundred day moving average price is $34.06.

Wall Street Analyst Weigh In

Several analysts have weighed in on AMLX shares. Bank of America started coverage on shares of Amylyx Pharmaceuticals in a research note on Thursday, January 5th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, February 15th. Finally, Citigroup increased their price target on shares of Amylyx Pharmaceuticals to $51.00 in a research note on Wednesday, November 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.20.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 3,586 shares of the firm’s stock in a transaction that occurred on Friday, February 24th. The shares were sold at an average price of $34.49, for a total value of $123,681.14. Following the transaction, the insider now directly owns 37,414 shares of the company’s stock, valued at $1,290,408.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 3,586 shares of the firm’s stock in a transaction that occurred on Friday, February 24th. The shares were sold at an average price of $34.49, for a total value of $123,681.14. Following the transaction, the insider now directly owns 37,414 shares of the company’s stock, valued at $1,290,408.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Morningside Venture Investment sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $33.75, for a total transaction of $1,687,500.00. Following the completion of the transaction, the insider now directly owns 7,480,598 shares in the company, valued at $252,470,182.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 103,586 shares of company stock valued at $3,547,681. 12.70% of the stock is currently owned by insiders.

About Amylyx Pharmaceuticals

(Get Rating)

Amylyx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.

See Also

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Rating).

Institutional Ownership by Quarter for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.